Mark Verratti compensation by year
MYRIAD GENETICS Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $434,489 | $464,423 | $495,781 | $552,344 | $622,883 |
| Bonus | — | — | $0 | $0 | $0 |
| Stock awards | $1,292,885 | $1,296,869 | $1,959,282 | $2,646,082 | $2,058,069 |
| Option awards | — | — | $0 | $0 | $0 |
| Non-equity incentive | $275,032 | $313,267 | $400,247 | $489,720 | $438,323 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $13,769 | $17,157 | $19,779 | $24,072 | $25,976 |
| Total | $2,016,175 | $2,091,716 | $2,875,089 | $3,712,217 | $3,145,251 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MYRIAD GENETICS INC DEF 14A filed April 14, 2026, accession 0000899923-26-000031, and prior-year filings.
How this page was built: the MYRIAD GENETICS INC filed document, accession 0000899923-26-000031. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 105,785 | $650,578 | — |
| RSU | 99,227 | $610,246 | — |
| RSU | 58,630 | $360,575 | — |
| RSU | 39,404 | $242,335 | — |
| RSU | 39,087 | $240,385 | — |
| RSU | 13,134 | $80,774 | — |
| RSU | 4,809 | $29,575 | — |
| RSU | 2,500 | $15,375 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in MYRIAD GENETICS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 14, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-06 | Grant or award derivative | — | 146,933 | $0.00 | 146,933 |
| 2026-04-14 | Tax withholding | — | 1,069 | $4.91 | 629,646 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
MYRIAD GENETICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Brian Donnelly | Chief Commercial Officer | $6,000,145 |
| Samraat Raha | President and Chief Executive Officer | $5,686,740 |
| Mark Verratti · this page | Chief Operating Officer | $3,145,251 |
| Scott Leffler | Former Chief Financial Officer | $2,736,493 |
| Margaret Ancona | Former EVP, Strategy and Transformation | $1,895,166 |
| Dale Muzzey | Chief Scientific Officer | $1,862,912 |
| Benjamin Wheeler | Chief Financial Officer | $1,507,897 |
| Paul Diaz | Former President and Chief Executive Officer | $688,637 |
Mark Verratti's compensation dossier, MYRIAD GENETICS
You have read Mark Verratti's totals and holdings. The dossier adds each equity grant MYRIAD GENETICS disclosed for Mark Verratti and MYRIAD GENETICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full MYRIAD GENETICS compensation record
free company briefThis page is one person within MYRIAD GENETICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MYRIAD GENETICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MYRIAD GENETICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MYRIAD GENETICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.